Albert Bourla, Pfizer CEO (Evan Vucci/AP Images)

Pfiz­er doles out $2.3B for blood can­cer play­er to flesh out its end-of-decade on­col­o­gy port­fo­lio

As its Covid-19 vac­cine rakes in cash, Pfiz­er is in a po­si­tion to move bold­ly as it looks at the hazy end of the cur­rent …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.